Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
by Zacks Equity Research
Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.
Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.
The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Merck & Co, Honeywell, 3M and General Electric
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
Top Stock Reports for Coca-Cola, Merck & Honeywell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola Company (KO), Merck (MRK) and Honeywell International (HON).
Model N (MODN) Q4 Earnings Beat, Stock Down on Bleak View
by Zacks Equity Research
Model N's (MODN) fourth-quarter fiscal 2020 results benefit from robust adoption of Revenue Cloud platform and strong sales execution. However, bleak guidance for fiscal 2021 remains a concern.
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.
AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View
by Zacks Equity Research
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Worried About Dow's Massive Crash? ETF & Stocks to Play
by Sanghamitra Saha
Rising fears of a second wave of lockdown globally sent Wall Street crashing on Wednesday with the Dow Jones being one of the worst hurt.
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
Wall Street Opens Green on Strong Economic Data
by Zacks Equity Research
Wall Street Opens Green on Strong Economic Data.